Evidence map›Paper›PMID 38289076›Full record

ArticleAntimicrobial agents and chemotherapy2024

Population pharmacokinetics and humanized dosage regimens matching the peak, area, trough, and range of amikacin plasma concentrations in immune-competent murine bloodstream and lung infection models.

Yuanyuan Jiao, Jun Yan, Dhruvitkumar S Sutaria, Peggy Lu, Michael Vicchiarelli, Zeferino Reyna, Juan Ruiz-Delgado, Elizabeth Burk, Eugene Moon, Nirav R Shah and 6 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Yuanyuan JiaoDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Jun YanDepartment of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Dhruvitkumar S SutariaDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Peggy LuDepartment of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Michael VicchiarelliInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.
Zeferino ReynaDepartment of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Juan Ruiz-DelgadoDepartment of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Elizabeth BurkDepartment of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Eugene MoonDepartment of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Nirav R ShahDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.
Brad SpellbergLos Angeles County-USC (LAC+USC) Medical Center, Los Angeles, California, USA.
Robert A BonomoDepartment of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.ORCID 0000-0002-3299-894X
George L DrusanoInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.ORCID 0000-0001-9162-7332
Arnold LouieInstitute for Therapeutic Innovation, College of Medicine, University of Florida, Orlando, Florida, USA.ORCID 0000-0001-6227-7580
Brian M LunaDepartment of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.ORCID 0000-0001-6718-4551
Jürgen B BulittaDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Orlando, Florida, USA.ORCID 0000-0001-7352-3097
University of Florida · USUniversity of Southern California · USLAC+USC Medical Center · USLouis Stokes Cleveland VA Medical Center · US

Funding

Combating resistant superbugs by understanding the molecular determinants of target site penetration and bindingR01AI136803 · NIAID · UNIVERSITY OF FLORIDA · PI BULITTA, JURGEN BERND · 2018 to 2022
$5.7M
Next-generation combination dosing strategies to combat resistant Acinetobacter baumanniiR01AI130185 · NIAID · UNIVERSITY OF FLORIDA · PI BULITTA, JURGEN BERND · 2018 to 2022
$3.4M
HHS | U.S. Food and Drug Administration (FDA) HHSF223201710199CNIAID NIH HHS R01 AI130185NIAID NIH HHS R01 AI136803
6 · The paper itself

Abstract

Amikacin is an FDA-approved aminoglycoside antibiotic that is commonly used. However, validated dosage regimens that achieve clinically relevant exposure profiles in mice are lacking. We aimed to design and validate humanized dosage regimens for amikacin in immune-competent murine bloodstream and lung infection models of

Indexed as

AmikacinPneumoniaAnimalsAnti-Bacterial AgentsBody WeightHumansLungMiceAmikacinAnti-Bacterial Agentsamikacinaminoglycosidebloodstream infectionlung epithelial lining fluidlung infectionmodel-based humanized dosage regimen designmouse/micemurine infection modelpopulation pharmacokineticsS-ADAPT

Identifiers

PMID38289076
PMCPMC10916399
OpenAlexW4391349268

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.